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OBJECTIVES: This study was designed to analyze drug utiliza-
tion and price trends, as well as to quantify market-share com-
petition among three major classes of medications used for the
treatment of breast cancer, including hormone therapies (HTs),
antineoplastic cytotoxic compounds (ACCs), and monoclonal
antibodies (MAs). METHODS: A total of 11 drugs were identi-
ﬁed regarding their perceived importance in clinic and were con-
tributed to the analysis. A retrospective time-series trend analysis
with three-year ahead forecasting was conducted. The quarter
utilization and reimbursement claims data from 1991 to 2005
were retrieved from the national Medicaid pharmacy ﬁles in the
Centers for Medicare & Medicaid Services. RESULTS: The total
US Medicaid expenditure on the identiﬁed 11 breast cancer med-
ications increased dramatically from $20.3 million in 1991 to
$142.1 in 2005. In parallel with the increased expenditure, the
total number of prescriptions swelled around 138 percent,
increasing from 261,952 to 607,208. The average reimburse-
ment price per prescription increased as well, jumping from
$77.41 in 1991 to $234.05 in 2005. The price of brand-name
drugs was signiﬁcantly affected when the generic version was
available in the market. Since the entry of trastuzumab (Her-
ceptin®) into market in 1998, its reimbursement market-share
has been increasing from 0.06% in 1998 to 11.2% in 2005 due
to its higher price compared to drugs in HTs and ACCs, while
its prescription market share only had slight increase. As pro-
jected, its market share will keep increasing to 19.98 % (95%CI,
12.97% to 27.00%) in 2008 4th quarter. By contrast, the reim-
bursement market-share of HTs decreased from 86.6% in 1991
to 49.2% in 2005. It was projected to be 42.48% (95% CI,
31.83% to 55.56%) in 2008 4th quarter. CONCLUSION: The
increased expenditure on breast cancer drugs might be attributed
by the rising utilization of newer and more expensive breast
cancer drugs.
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OBJECTIVES: To assess the burden of illness and costs associ-
ated with managing patients with bone pain secondary to
metastatic prostate cancer, using 153Sm-lexidronam as palliative
therapy. METHODS: Medical records of a convenience sample
of 712 patients undergoing palliative treatment for metastatic
prostate hormone-refractory adenocarcinoma (androgen-
independent prostate cancer) at US VA facilities between March
2000 and December 2002 were reviewed. Of this population, 85
patients [11.9%] received 153Sm-lexidronam, 299 [42.1%]
underwent external beam radiation therapy [EBRT], 167
[23.4%] received pamidronate disodium, 42 [6.6%] received
mitoxantrone, and 119 [16.7%] were principally treated by
opioid analgesics. Patients were treated to achieve optimum pain
control. Resource utilization data were collected for 12 months
commencing with initial referral for cancer pain management.
Sociodemographic characteristics, laboratory values, and charge
data scores were analyzed using descriptive statistics and
unpaired Student’s t-test in a cross-sectional study design.
RESULTS: No statistically signiﬁcant inter-group differences
were observed in patient sociodemographic characteristics and
PSA levels. During the 12-month observation interval considered
for this analysis, opioid-based palliation was most costly with
in-patient charges comprising the greatest portion of all charges,
whereas EBRT was most costly according to out-patient charges.
153Sm-lexidronam-based management was least costly in terms
of both in-patient and out-patient charges. CONCLUSION: The
costs associated with the use of 153Sm-lexidronam, a radiophar-
maceutical previously demonstrated as safe and effective in the
management of patients with metastatic prostate cancer, are no
higher, and generally less, than most other options. Therefore,
153Sm-lexidronam should be considered a low cost intervention
when compared to other palliative management options in man-
aging bone pain secondary to metastatic prostate cancer.
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OBJECTIVES: To understand current utilization patterns, this
study examined real-world treatment patterns and treatment
costs for epoetin alfa (EPO) and darbepoetin alfa (DARB), two
erythropoietic stimulating agents (ESA), as well as red blood cell
(RBC) transfusion requirements in cancer patients. METHODS:
Analysis of medical claims between 1/2004 and 2/2006 from the
Integrated Health Care Information Services (IHCIS) national
database from over 35 health plans nationwide was conducted.
Patients included were ≥18 years old, had ≥1 claim for cancer
within 90 days prior to treatment initiation, were newly initiated
on EPO or DARB, and received ≥2 doses. Mean cumulative ESA
dose was used to calculate drug cost (based on 9/2006 WAC)
and dose ratio (Units EPO : mcg DARB). The proportion of
patients transfused during treatment was compared between the
two groups. RESULTS: A total of 4008 EPO and 3039 DARB
patients formed the study population. EPO patients were older
(60.4 vs. 58.4 years, p < 0.0001) and a lower proportion were
women (63% vs. 67%, p = 0.0006), compared to DARB
patients. Mean treatment duration was similar for both groups
(EPO: 58 days; DARB: 57 days; p = 0.3690). Mean (SD) cumu-
lative dose administered was 278,783 (259,569) Units for the
EPO group and 1118 mcg (949) for the DARB group, resulting
in a dose ratio of 249 : 1 (Units EPO : mcg DARB) and signiﬁ-
cantly higher drug cost in the DARB group (EPO $3393, DARB
$4971, p < 0.0001). RBC transfusion was administered to 6.1%
of EPO patients compared to 8.0% of DARB patients (p =
0.002). CONCLUSION: This observational study of over 7000
cancer patients reported a dose ratio of 249 : 1 (Units EPO: mcg
DARB), 46% higher DARB drug cost, and signiﬁcantly higher
transfusion rate in the DARB group compared to the EPO group.
These ﬁndings provide greater understanding of current real-
world ESA utilization in the managed care setting and corrobo-
rate earlier ﬁndings in this population.
